Drug
SR57667B
SR57667B is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease
NCT00228150
completedphase_2
Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease
NCT00220272
completedphase_2
Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
NCT00285077
completedphase_2
Study of the Effect of SR57667B in Patients With Alzheimer's Disease
NCT00285025
Clinical Trials (4)
Showing 4 of 4 trials
NCT00228150Phase 2
Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease
NCT00220272Phase 2
Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease
NCT00285077Phase 2
Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
NCT00285025Phase 2
Study of the Effect of SR57667B in Patients With Alzheimer's Disease
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4